Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment

NCT06978062 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

27

Enrollment

NETWORK

Sponsor class

Conditions

GastroEsophageal Cancer

Interventions

DRUG: Bemarituzumab
DRUG: FLOT

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC